Clinical studies included: a post-marketing surveillance study involving patients with pressure sores/venous leg ulcers/diabetic foot ulcers/traumatic wounds (n=12,400) treated with an activated charcoal dressing with silver; a randomised control trial (RCT) involving patients with diabetic foot ulcers (n=40) treated with collagen/oxidised regenerated cellulose (ORC)/silver or the standard of care; a RCT involving patients with venous leg ulcers/pressure ulcers (n=99) treated with an antimicrobial alginate dressing with silver or a calcium-alginate dressing; and a clinical study involving 20 patients with chronic wounds treated with a non-adherent antimicrobial alginate dressing with silver.
Results from the post-marketing surveillance study showed that the overall healing rate was 35.5% and 49.3% for 6 and 12 weeks treatment with the activated charcoal dressing with silver, respectively. In the RCT with collagen/ ORC/silver, all patients were protected from infection compared with the control group, where 33% patients were withdrawn due to infection (p=0.012). Of the patients in the RCT receiving the antimicrobial alginate dressing with silver, the 4-week closure rate was greater than for the control group (0.32 +/- 0.5cm2 vs 0.16 +/- 0.40cm2; p=0.024). Patients receiving the non-adherent antimicrobial alginate dressing with silver experienced less pain at dressing change than those receiving the control (0/10 vs 9/10).
There is a wealth of clinical evidence to support the efficacy of silver-dressings in wound management. Silver-dressings can assist wound healing and enhance patient quality of life by controlling infection, odour and pain.